These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19827892)

  • 1. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
    Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
    Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin's lymphoma patients.
    Soydinc HO; Guney N; Basaran M; Duranyildiz D; Yasasever V
    Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor.
    Blay JY; Burdin N; Rousset F; Lenoir G; Biron P; Philip T; Banchereau J; Favrot MC
    Blood; 1993 Oct; 82(7):2169-74. PubMed ID: 8400266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
    Ozdemir F; Aydin F; Yilmaz M; Kavgaci H; Bektas O; Yavuz MN; Yavuz AA
    J Exp Clin Cancer Res; 2004 Sep; 23(3):485-8. PubMed ID: 15595640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma.
    Aydin F; Yilmaz M; Ozdemir F; Kavgaci H; Yavuz MN; Yavuz AA
    Am J Clin Oncol; 2002 Dec; 25(6):570-2. PubMed ID: 12478000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
    Pedersen LM; Klausen TW; Davidsen UH; Johnsen HE
    Ann Hematol; 2005 Aug; 84(8):510-6. PubMed ID: 15834569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma interleukin-6 and interleukin-10 levels in different subtypes of lymphoma and their clinical significance].
    Wang X; Zhao HR; Gu X; Liu P; Bikmituofu H
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Aug; 31(8):1360-4. PubMed ID: 21868324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors.
    Inagaki A; Ishida T; Ishii T; Komatsu H; Iida S; Ding J; Yonekura K; Takeuchi S; Takatsuka Y; Utsunomiya A; Ueda R
    Int J Cancer; 2006 Jun; 118(12):3054-61. PubMed ID: 16425276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
    Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
    Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
    Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
    Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
    Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma.
    Legouffe E; Rodriguez C; Picot MC; Richard B; Klein B; Rossi JF; Commes T
    Leuk Lymphoma; 1998 Oct; 31(3-4):351-7. PubMed ID: 9869199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
    Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
    Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma.
    el-Far M; Fouda M; Yahya R; el-Baz H
    J Physiol Biochem; 2004 Dec; 60(4):253-8. PubMed ID: 15957243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
    Zidan J; Hussein O; Basher W; Zohar S
    Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
    Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M
    Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas.
    Stasi R; Conforti M; Del Poeta G; Simone MD; Coppetelli U; Tribalto M; Cantonetti M; Perrotti A; Venditti A; Papa G
    Haematologica; 1992; 77(6):518-21. PubMed ID: 1289190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of serum lactate dehydrogenase, β2-microglobulin and vascular endothelial growth factor level detection in patients with non-Hodgkin's lymphoma].
    Duan Y; Li G; Hu HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):608-10. PubMed ID: 22739165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.